Javier Delgado-Lista, Jose M Mostaza, Teresa Arrobas-Velilla, Francisco Blanco-Vaca, Luis Masana, Juan Pedro-Botet, Pablo Perez-Martinez, Fernando Civeira, Jose I Cuende-Melero, Jose J Gomez-Barrado, Carlos Lahoz, Xavier Pintó, Manuel Suarez-Tembra, Jose Lopez-Miranda, Carlos Guijarro
The irruption of lipoprotein(a) (Lp(a)) in the study of cardiovascular risk factors is perhaps, together with the discovery and use of proprotein convertase subtilisin/kexin type 9 (iPCSK9) inhibitor drugs, the greatest novelty in the field for decades. Lp(a) concentration (especially very high levels) has an undeniable association with certain cardiovascular complications, such as atherosclerotic vascular disease (AVD) and aortic stenosis. However, there are several current limitations to both establishing epidemiological associations and specific pharmacological treatment...
April 9, 2024: Clínica e Investigación en Arteriosclerosis